Our investigators have identified a generic drug, SW-01, that is a highly selective RET kinase inhibitor. RET is well established as an important cancer-causing molecule in human thyroid cancer and recent findings support a broader role in neuroblastoma, lung tumours, estrogen receptor-positive breast cancer, and pancreatic tumours. The efficacy of SW-01 was demonstrated in pancreatic cancer Xenografts. Unlike other kinase inhibitors, SW-01 is highly selective and it inhibits RET mutants other RET Inhibitors can’t. It has a well-defined safety-profile and lacks toxicities associated with other kinase inhibitors.
The in vitro use of cyclobenzaprine in combination with gemcitabine demonstrated potent synergy on pancreatic cancers and this was validated in preclinical models of pancreatic cancer. Furthermore, toxicology studies have identified safe concentrations of the combination for treatment. This unique synergy should translate into success in treating pancreatic cancer – the deadliest form of cancer.
- Unique and potent synergy with gemcitabine for treating pancreatic cancer
- Broad Efficacy in treating RET-specific cancers like thyroid cancer
- Proven safety profile and quick to clinic
Intellectual Property Status:
National Phase Entrance into Canada, US and European Region
PARTEQ Innovations, the technology transfer office of Queen’s University, is seeking industrial partners willing to support ongoing development of the product and/or who are interested in licensing the intellectual property.
Download PDF version of this technology description: http://parteq.technologypublisher.com/files/sites/tob---8.5-x-11---colour-sw-01-ret-kinase-inhibitor.pdf